Pharma BD Deal Intelligence
Roche's $1.2B bet on integrated diabetes management collapsed within a year, when an FDA manufacturing ban gutted Disetronic's US insulin-pump business and the unit never recovered.
Full analysis, sources & comparables →Swiss Roche to buy insulin pump maker Disetronic for SF1.6bn, combining pump leadership with Roche's existing diabetes diagnostics business.
Roche's Disetronic acquisition characterized as 'how to blow a billion bucks' after manufacturing setbacks and competitive losses to Medtronic forced US pump…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
SFr1.6B (~$1.18B) for Swiss insulin pump leader, completed February 10, 2003. Combined with Roche diabetes monitoring. Sources: ICIS 2/10/2003, Crunchbase, swissinfo.
Roche's $1.2B bet on integrated diabetes management collapsed within a year, when an FDA manufacturing ban gutted Disetronic's US insulin-pump business and the unit never recovered.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Disetronic Holding AG (this deal) | 2003 | $1.2B | 22 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2003 deals · Roche Holding AG deals